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Evidence That Familial Liability for Psychosis
Is Expressed as Differential Sensitivity to Cannabis
An Analysis of Patient-Sibling and Sibling-Control Pairs
Genetic Risk and Outcome in Psychosis (GROUP) Investigators
Context: Individual differences in cannabis sensitivity may
be associated with genetic risk for psychotic disorder.
Objectives: To demonstrate and replicate, using 2 con-
ceptually different genetic epidemiological designs, that
(familial) liability to psychosis is associated with sensi-
tivity to cannabis.
Design, Setting, and Participants: Sibling-control
and cross-sibling comparisons using samples of pa-
tients with a psychotic disorder (n=1120), their sib-
lings (n=1057), and community controls (n=590) in the
Netherlands and Flanders.
MainOutcomeMeasures: Positive and negative schizo-
typy using the Structured Interview for Schizotypy–
Revised (for siblings and controls) and self-reported posi-
tive and negative psychotic experiences using the
Community Assessment of Psychic Experiences (for sib-
lings and patients). Cannabis use was assessed as cur-
rent use (by urinalysis) and lifetime frequency of use (by
Composite International Diagnostic Interview).
Results: In the sibling-control comparison, siblings dis-
played more than 15 times greater sensitivity to positive
schizotypy associated with particularly current cannabis
use by urinalysis (adjusted B=0.197, P .001) than con-
trols (adjusted B=0.013, P=.86) (P interaction=.04) and
a similar difference in sensitivity to its effect on negative
schizotypy (siblings: adjusted B=0.120, P .001; con-
trols:B=−0.008, P=.87; P interaction=.03). Similarly, sib-
lings exposed to cannabis resembled their patient relative
nearly 10 times more closely in the positive psychotic
dimension of the Community Assessment of Psychic Ex-
periences (adjusted B=0.278, P .001) compared with
nonexposed siblings (adjusted B=0.025, P=.12) (P inter-
action .001). No significant effect was apparent for the
Community Assessment of Psychic Experiences negative
domain, although the association was directionally simi-
lar (2 times more resemblance; P interaction=.17). Cross-
sibling, cross-trait analyses suggested that the mecha-
nism underlying these findings was moderation (familial
risk increasing sensitivity to cannabis) rather than media-
tion (familial risk increasing use of cannabis).
Conclusions: Genetic risk for psychotic disorder may
be expressed in part as sensitivity to the psychotomi-
metic effect of cannabis. Cannabis use may synergisti-
cally combine with preexisting psychosis liability to cause
positive and negative symptoms of psychosis.
Arch Gen Psychiatry. 2011;68(2):138-147.
Published online October 4, 2010.
doi:10.1001/archgenpsychiatry.2010.132
R ANDOMIZED CONTROLLEDexperiments have shownthat acute exposure to9-tetrahydrocannabinol,the main psychotropic
component of Cannabis sativa, induces
psychotic symptoms in a substantial
proportion of healthy controls.1 , 2
Meta-analysis3,4 of prospective epidemio-
logical studies indicates that cannabis use
not only predicts onset of psychotic dis-
order but also is associated with subthresh-
old expression of psychosis either in the
form of schizotypy5-7 or subclinical psy-
chotic experiences.8-10 Schizotypy and sub-
clinical psychotic experiences represent re-
lated phenotypes; the positive and negative
dimensions of the Structured Interview for
Schizotypy–Revised (SIS-R) correlate
strongly with the equivalent dimensions
of self-reported psychotic experiences,11
and both measures of schizotypy and mea-
sures of subclinical psychotic experi-
ences display familial clustering with psy-
chotic disorder.12-18 The results therefore
See also page 148
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suggest that cannabis may provoke a psychotic re-
sponse in individuals with higher-than-average vulner-
ability for psychotic disorder.
Follow-up experimental and observational work in-
deed has suggested that psychosis liability is associated with
differential sensitivity to the psychotomimetic effects of
9-tetrahydrocannabinol.2,5,8,10,19,20 Differential sensitiv-
ity to the psychotomimetic effects of 9-tetrahydrocan-
nabinol has been linked to both familial/genetic fac-
tors21-23 and environmental exposures including childhood
trauma,24,25 suggesting that complicated interactions be-
tween genetic and environmental factors over the life course
may affect adult cannabis sensitivity. The findings to date
suggest that genes may interact with early environmental
exposures associated with psychotic disorder, creating a
sensitized state26 with regard to later exposure to canna-
bis and the onset of psychotic symptoms.27
Interacting causes are difficult to examine and re-
quire large samples and special designs.28 The initial fo-
cus was therefore on indirect, nonmolecular measures
of genetic risk that, although not precise with regard to
molecular variation, represent the first stage of exami-
nation given the unique possibility to model net genetic
contribution in low-power interaction paradigms.29
The indirect measure of genetic risk used in this study
was sibling status given that the risk for schizophrenia
in siblings of patients is increased 5- to 10-fold, and twin
studies indicate that familial clustering is mainly due to
genetic factors.30 A sibling thus represents an individual
who is genetically at higher-than-average risk for psy-
chotic disorder, allowing for a sibling-control compari-
son of the hypothesis that genetic risk for psychotic dis-
order is expressed in part as sensitivity to the effect of
cannabis using interview-based schizotypy as the out-
come. The advantage of a sibling-based design to test for
differential sensitivity to an environmental exposure is
that it avoids the confounds and biases occasioned by the
presence of illness and its treatment with antipsychotic
medication. An added advantage is that a sibling-based
design may aid in teasing apart moderation (genetic con-
trol of sensitivity to the psychotomimetic effects of can-
nabis) from mediation (genetic control of exposure to can-
nabis; more details follow later).31 Finally, a design based
on 2 siblings pertaining to the same family effectively con-
trols for a range of unobserved and unmeasured con-
founding factors given that siblings share a range of so-
cioeconomic and developmental circumstances.32
A combined unaffected sibling–control (sibling-
control) and patient–unaffected sibling (cross-sibling) de-
sign was used to examine the hypothesis that familial li-
ability to psychotic disorder is associated with differential
sensitivity to the psychotomimetic effects of cannabis. The
sibling-control design is based on the prediction that the
psychotomimetic effect of cannabis in unaffected sib-
lings at higher-than-average genetic risk for psychotic dis-
order is greater than the psychotomimetic effect of can-
nabis in healthy controls. The cross-sibling design is based
on the prediction that in unaffected siblings who are not
exposed to cannabis, vulnerability for psychosis will re-
main largely latent and is expressed at a low level of schizo-
typal symptoms. Thus, when the degree of sibling re-
semblance for psychosis is examined (by calculating the
phenotypic correlation for expression of psychosis be-
tween the patient and the unaffected sibling), the corre-
lation will be low. However, when the unaffected sib-
ling is exposed to cannabis, latent psychosis vulnerability
may become expressed to a greater degree, at the level
of schizotypal symptoms. This would cause the pheno-
typic correlation between the patient and the unaffected
sibling to become more visible, reflecting familial differ-
ences in the tendency to express psychotic symptoms.33-35
METHODS
SUBJECTS
Data pertain to baseline measures of an ongoing longitudinal study
(Genetic Risk and Outcome in Psychosis [GROUP]) in Europe.
In selected representative geographical areas in the Netherlands
and Belgium, patients were identified through representative cli-
nicians working in regional psychotic disorder services whose case-
loads were screened for inclusion criteria. Subsequently, a group
of patients presenting consecutively at these services as either out-
patients or inpatients were recruited for the study. Controls were
selected through a system of random mailings to addresses in the
catchment areas of the cases.
The full GROUP sample consisted of 1120 patients with
nonaffective psychotic disorder, 1057 siblings of these 1120
patients, 919 parents of the patients and their siblings, and
590 unrelated controls. Inclusion criteria were the following:
(1) age range of 16 to 50 years; (2) diagnosis of nonaffective
psychotic disorder; and (3) good command of the Dutch lan-
guage. Controls had no first-degree relative with a psychotic
disorder as established by the Family Interview for Genetic
Studies36 with the control as informant. Diagnosis was based
on the DSM-IV-TR criteria,37 assessed with the Comprehen-
sive Assessment of Symptoms and History interview38 or
Schedules for Clinical Assessment for Neuropsychiatry ver-
sion 2.1.39 The DSM-IV-TR diagnoses of the patients were as
follows: schizophrenia and related disorders (DSM-IV-TR
code 295.x; n=945 [84%]), other psychotic disorders (DSM-
IV-TR code 297/298; n=149 [13%]), and psychotic illness in
the context of substance abuse or somatic illness (n=9 [1%]).
Six patients had a missing diagnosis but fulfilled inclusion cri-
teria, and 11 patients had a final diagnosis of affective psycho-
sis but fulfilled criteria of clinical diagnosis of nonaffective
psychosis at study entry; these individuals were retained in
the sample assuming subtle diagnostic changes between the
time of identification for inclusion and actual assessment that
could occur in any patient included in the cohort at any time
and taking into account that for the focus of underlying
genetic liability the diagnostic change would not be relevant.40
In the sibling and control groups, there were 149 participants
(14%) and 59 participants (10%), respectively, with a history
of a common mental disorder, the great majority of whom had
a mood disorder (DSM-IV-TR code 296.x).
The study was approved by the standing ethics committee,
and all of the subjects gave written informed consent in accor-
dance with the committee’s guidelines.
SUBSTANCE USE
Substance use was assessed using the Composite International
Diagnostic Interview (CIDI) sections B, J, and L41 and through
urinalysis. Two different definitions of cannabis exposure were
used in the analyses: (1) CIDI cannabis pattern of use during the
lifetime period of heaviest use (hereafter calledCIDI lifetime use):
none (scored as 0), less than weekly (scored as 1), weekly (scored
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as 2), and daily (scored as 3); and (2) current cannabis use as-
sessed by urinalysis (hereafter called current use): none (scored
as 0) and present (scored as 1). Urinalysis was carried out as a
screen for the presence of cannabis at the national Alcohol and
Drug Use Jellinek Laboratory. The method used was immuno-
assays with a cutoff of 50 ng/mL. In addition, as an integrity pa-
rameter, the creatinine level of every sample was measured. Can-
nabis urine screening has a detection window of up to 30 days,
but the detection time has been documented in literature to be
even longer (up to 3 months) depending on the level of cannabis
use.42 Given the relatively high cutoff level of 50 ng/mL, a con-
servative detection window of 1 month can be inferred.
PSYCHOSIS MEASURES
For the sibling–healthy control comparison, an interview-
based measure of schizotypy was used. For the patient–
unaffected sibling cross-sibling design, a self-reported mea-
sure of psychotic symptoms was used given that interviews based
on clinical instruments are not suitable for nonpatients (floor
effects) and schizotypy interviews are not suitable for patients
(ceiling effects).
Interview-Based Psychosis Measures
The SIS-R43,44 was administered to controls and siblings. The
SIS-R is a semistructured interview containing 20 schizotypal
symptoms and 11 schizotypal signs rated on a 4-point scale.
Symptoms are defined as verbal responses to standardized ques-
tions concerning, for example, magical ideation, illusions, and
referential thinking. Signs refer to behaviors that are rated by
the interviewer such as goal directedness of thinking and flat-
ness of affect. Questions and rating procedures are standard-
ized. Guided by previous research,33 item scores were reduced
a priori to 2 dimensional scores, representing the means of posi-
tive schizotypy items (referential thinking, psychotic phenom-
ena, derealization, magical ideation, illusions, and suspicious-
ness; score range, 0-2.7) and negative-disorganized schizotypy
items (social isolation, sensitivity, introversion, restricted affect,
disturbances in associative and goal-directed thinking, pov-
erty of speech, and eccentric behavior; score range, 0-1.8).
Self-report Psychosis Measures
The Community Assessment of Psychic Experiences (CAPE;
http://cape42.homestead.com) was developed to rate self-
reports of lifetime psychotic experiences and was completed
by patients and their siblings. Items are modeled on patient ex-
periences as contained in the Present State Examination, ninth
edition45 and the schedules assessing negative symptoms such
as the Scale for the Assessment of Negative Symptoms46 and
the Subjective Experience of Negative Symptoms.47 Items are
scored on a 4-point scale. In the current analyses, CAPE di-
mensions of frequency of positive experiences (20 items) and
negative experiences (14 items) were included, representing
the person’s perceived psychosis load over the lifetime. A total
score representing the mean of all items was calculated for each
dimension and weighted for partial nonresponse (CAPE posi-
tive: score range, 0-2.9; CAPE negative: score range, 0-2.8). Pre-
vious research with the CAPE has yielded the following: (1) a
factor structure with separate positive and negative dimen-
sions in a large and representative sample of young men48 and
in a large sample of undergraduate female students9; (2) dis-
criminative validity across groups of individuals with schizo-
phrenia, affective disorders, and anxiety disorders and indi-
viduals from the general population49; (3) family-specific
variation for positive and negative subclinical psychosis di-
mensions33; and (4) stability over time and specific and inde-
pendent associations with the corresponding dimensions based
on interview.11
ANALYSIS
Approach 1: Sibling-Control Using SIS-R
The moderation model operates on the assumption that the re-
lationship between cannabis use and psychotic symptoms
changes as a result of the copresence of a family history of psy-
chotic disorder, indexed by sibling illness status. Thus, in the
sibling-control design, continuous SIS-R scores were re-
gressed on cannabis use, sibling-control status, and their in-
teraction. Given that some families contributed more than 1
sibling, hierarchical clustering of data at the level of family was
modeled using the multilevel random regression XTREG rou-
tine in STATA version 11 statistical software (StataCorp LP, Col-
lege Station, Texas). In the case of significant interaction, strati-
fied effect sizes were calculated using the appropriate linear
combinations from the interaction model with the STATA
LINCOM routine.
Approach 2: Cross-Sibling Associations Using CAPE
In the case of genetic influence on differential sensitivity to the
psychotomimetic effects of cannabis, one prediction is that the
sibling correlation should be higher in exposed environ-
ments.28 Therefore, in this study, correlations in the level of
CAPE psychosis measures were calculated for patient–
unaffected sibling pairs as a function of cannabis use in the un-
affected sibling. To model these relationships in patient-
sibling pairs, the continuous CAPE positive and negative
dimensions in the unaffected sibling were regressed on canna-
bis use in the unaffected sibling, the corresponding CAPE di-
mension in the patient, and their interaction. In the case of fami-
lies contributing more than 1 patient or more than 1 sibling,
all possible patient–unaffected sibling pairs were included in
the analyses. As some families thus contributed more than 1
sibling pair, the STATA multilevel random regression XTREG
routine was used, followed by calculation of stratified effect sizes
as explained earlier.
Adjustment for Other Drug Use
Analyses using the CIDI cannabis exposure were adjusted for CIDI
variables indicating lifetime use of other psychotomimetic drugs,
defined as stimulants, cocaine, 1-(1-phenylcyclohexyl)
piperidine (PCP), psychedelics, and other drugs (3,4-
methylenedioxymethamphetamine [MDMA], alkyl nitrites, de-
signer drugs), scored as none (0) and present (1).
Analyses using the urinalysis cannabis exposure were ad-
justed for the use of other drugs assessed with urinalysis: pres-
ence of cocaine (benzoylecgonine) and amphetamines/
MDMA. Cloned enzyme donor immunoassays were used with
a cutoff of 300 ng/mL for cocaine and a cutoff of 1000 ng/mL
for amphetamine/MDMA, with additional analyses added when
the first screening result was positive.
As both CIDI lifetime cannabis use and current cannabis use
by urinalysis were associated not only with case-sibling-control
status but also with age (in years), sex (0=men, 1=women), eth-
nicity (0=white, 1=nonwhite), and educational level (for cat-
egories, see Table1) and as various a priori conservative (in the
direction of the null hypothesis of no association) and anticon-
servative (in the direction of rejection of the null hypothesis) con-
founding mechanisms may be plausibly hypothesized, adjusted
estimates included correction for these variables.
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In the cross-sibling analyses, estimates were adjusted for val-
ues of confounders (demographic characteristics, drug use) of
both siblings.
Mediation vs Moderation
In the sibling-control comparison, moderation (genetic control
of sensitivity to the psychotomimetic effects of cannabis) can-
not be distinguished directly from mediation (genetic control of
exposure to cannabis). In other words, it is important to distin-
guish whether findings are due to familial risk for psychotic dis-
order making a person more sensitive to cannabis (modera-
tion) or to familial risk for psychotic disorder making a person
more likely to start using cannabis (mediation). Mediation may
be relevant because patients more often used cannabis than sib-
lings, and siblings in turn more often used cannabis than con-
trols (Table 1). To examine the possibility of mediation, we ex-
amined the cross-sibling cross-trait association between cannabis
(both current use as assessed by urinalysis and lifetime use as
assessed with the CIDI and recoded dichotomously as 0=no use
vs 1=any use) and psychosis by regressing, using multilevel lo-
gistic regression in STATA statistical software, (1) cannabis use




or F (df )a P ValueNo. (%) Total No. No. (%) Total No. No. (%) Total No.
Age, mean (SD), y 30.4 (10.6) 590 27.8 (8.3) 1057 27.7 (8.1) 1120 22.0 (2,2764) .001
Male 270 (46) 590 482 (46) 1057 853 (76) 1120 254.6 (2) .001
Education 590 1057 1120 255.9 (12) .001
None/primary only 16 (3) 79 (8) 141 (13)
Lower secondary 86 (15) 202 (19) 340 (30)
Lower vocational 91 (15) 231 (22) 185 (17)
Higher secondary 185 (31) 208 (20) 266 (24)
Higher vocational 149 (25) 187 (18) 100 (9)
University 58 (10) 122 (12) 44 (4)
Unknown 5 (1) 28 (3) 43 (4)
White 530 (90) 590 877 (83) 1057 857 (77) 1120 47.6 (2) .001
Living together 235 (41) 573 411 (40) 1019 96 (9) 1041 305.9 (2) .001
CIDI pattern of cannabis use 590 1057 1120 384.3 (6) .001
None 428 (75) 660 (62) 434 (39)
Less than weekly 79 (13) 145 (14) 93 (8)
Weekly 40 (7) 101 (10) 120 (11)
Daily 43 (7) 151 (14) 473 (42)
Positive for cannabis use
by urinalysis
27 (5) 556 75 (8) 956 158 (16) 964 61.6 (2) .001
Positive drug use by CIDI
Cocaine 27 (5) 590 86 (8) 1057 244 (22) 1120 136.4 (2) .001
Stimulants 23 (4) 590 69 (7) 1057 239 (21) 1120 159.6 (2) .001
PCP 1 (0.2) 590 1 (0.1) 1057 7 (1) 1120 5.3 (2) .07
Psychedelics 21 (4) 590 60 (6) 1057 210 (19) 1120 137.3 (2) .001
Other 33 (6) 590 119 (11) 1057 292 (26) 1120 149.4 (2) .001
Positive drug use by urinalysis
Cocaine 1 (0.2) 555 10 (1) 956 13 (1) 965 5.1 (2) .08
Amphetamines/MDMA 1 (0.2) 547 5 (1) 931 8 (1) 945 2.7 (2) .26
SIS-R score, mean (SD)
Positive 0.32 (0.35) 580 0.38 (0.42) 1038 . . . . . . 10.2 (1,1616) .001
Negative 0.24 (0.23) 579 0.27 (0.26) 1038 . . . . . . 7.1 (1,1615) .008
CAPE score, mean (SD)
Positive . . . . . . 0.21 (0.20) 916 0.67 (0.49) 869 535.1 (2,2344) .001
Negative . . . . . . 0.55 (0.38) 916 1.02 (0.54) 869 360.9 (2,2344) .001
PANSS score, mean (SD)
Positive . . . . . . . . . . . . 13.9 (6.6) 1023 . . . . . .
Negative . . . . . . . . . . . . 15.0 (6.7) 1013 . . . . . .
Abbreviations: CAPE, Community Assessment of Psychic Experiences; CIDI, Composite International Diagnostic Interview;
MDMA, 3,4-methylenedioxymethamphetamine; PANSS, Positive and Negative Syndrome Scale; PCP, 1-(1-phenylcyclohexyl)piperidine; SIS-R, Structured
Interview for Schizotypy–Revised; ellipses, not applicable.

























Frequency of Cannabis Use
None Less Than Weekly Weekly Daily
Figure 1. Structured Interview for Schizotypy–Revised (SIS-R) positive
schizotypy score as a function of lifetime frequency of cannabis use in
controls and siblings of patients with a psychotic disorder.
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in the sibling on CAPE positive psychotic experiences in the pa-
tient controlling for age, sex, ethnic group, and educational level
of both the sibling and the patient and (2) cannabis use in the
patient on CAPE positive psychotic experiences in the sibling
similarly adjusted for age, sex, ethnicity, and educational level.
A positive association would be suggestive of familial risk for psy-
chotic disorder predisposing for both cannabis use and CAPE
positive psychotic experiences. The mediation model thus op-
erates under the assumption that the association between an en-
vironmental factor (cannabis) and a psychopathological out-
come (CAPE psychotic symptoms) across related individuals at




The sample consisted of 590 controls and 1066 families
who contributed 1057 siblings and 1120 patients with
nonaffective psychotic disorder. Families contributed a
single patient (206 families, 206 subjects), a single sib-
ling (6 families, 6 subjects), a patient and a sibling (634
families, 1268 subjects), 2 patients (25 families, 50
subjects), 1 patient and 2 siblings (130 families, 390 sub-
jects), 2 patients and 1 sibling (15 families, 45 sub-
jects), 3 patients (2 families, 6 subjects), 1 patient and 3
siblings (28 families, 112 subjects), 2 patients and 2 sib-
lings (5 families, 20 subjects), 3 patients and 1 sibling
(1 family, 4 subjects), 4 patients (1 family, 4 subjects), 1
patient and 4 siblings (8 families, 40 subjects), 2 pa-
tients and 3 siblings (2 families, 10 subjects), 3 patients
and 2 siblings (2 families, 10 subjects), and 1 patient and
5 siblings (1 family, 6 subjects).
The median illness duration of patients was 3.3 years
(interquartile range, 1.3-6.2 years), and the mean (SD)
Global Assessment of Functioning scores were 56 (16)
for Global Assessment of Functioning symptoms and 55
(16) for Global Assessment of Functioning disability.
Patients and their siblings more often used cannabis than
controls and more often were male and nonwhite. Use of
other drugs was also more common in siblings and pa-
tients (Table 1). The SIS-R positive and negative dimen-
sions in controls and siblings were moderately correlated
(r=0.50, P .001), as were the CAPE positive and nega-
tive dimensions in patients and siblings (r=0.62,P .001).
SIBLING-CONTROL STUDY USING SIS-R
The association between CIDI lifetime use and positive
schizotypy assessed with the SIS-R was stronger in sib-
lings than in controls (adjusted interaction 2=4.51,
P=.03) (Figure 1 and Table 2), and a similar result
was apparent for negative schizotypy (adjusted interac-
tion 2=4.16, P=.04) (Figure 2 and Table 2). Simi-
larly, the association between current cannabis use by uri-
nalysis and schizoptypy was stronger in siblings compared
with controls for both the positive (adjusted interaction
2=4.19, P=.04) (Figure 3 and Table 3) and negative
(adjusted interaction 2=4.95, P=.03) (Figure 3 and
Table 3) dimensions.
Table 2. Composite International Diagnostic Interview Lifetime Cannabis Use and Schizotypy in Controls and Siblings of Patients






















None 0.32 (0.35) 420 0c . . . 0.35 (0.38) 644 0c . . . 0c . . .
Less than weekly 0.29 (0.37) 78 −0.002 (−0.093 to 0.089) .97 0.36 (0.41) 145 0.009 (−0.058 to 0.076) .79 0.03 .85
Weekly 0.27 (0.30) 39 −0.084 (−0.207 to 0.039) .18 0.42 (0.48) 100 0.084 (0.005 to 0.163) .04 5.20 .02
Daily 0.44 (0.38) 43 0.109 (−0.016 to 0.235) .09 0.54 (0.50) 149 0.185 (0.109 to 0.261) .001 1.18 .28
Unadjusted B
linear trendd
0.016 (−0.018 to 0.051) .36 0.056 (0.035 to 0.076) .001 3.66 .06
Adjusted B
linear trenda,d
0.012 (−0.024 to 0.047) .53 0.055 (0.031 to 0.078) .001 4.51 .03
Negative Schizotypy
None 0.25 (0.23) 420 0c . . . 0.27 (0.26) 644 0c . . . 0c . . .
Less than weekly 0.20 (0.19) 77 −0.047 (−0.106 to 0.013) .12 0.22 (0.18) 145 −0.055 (−0.099 to −0.012) .01 0.05 .82
Weekly 0.18 (0.21) 39 −0.080 (−0.160 to 0.003) .049 0.25 (0.22) 100 −0.014 (−0.065 to 0.038) .61 1.92 .17
Daily 0.27 (0.22) 43 0.022 (−0.059 to 0.103) .60 0.36 (0.33) 149 0.079 (0.029 to 0.129) .002 1.61 .20
Unadjusted B
linear trendd
−0.008 (−0.030 to 0.014) .47 0.021 (0.007 to 0.034) .003 4.69 .03
Adjusted B
linear trenda,d
−0.012 (−0.035 to 0.012) .33 0.015 (0.001 to 0.031) .049 4.16 .04
Abbreviations: CI, confidence interval; CIDI, Composite International Diagnostic Interview; SIS-R, Structured Interview for Schizotypy–Revised; ellipses, not
applicable.
aAdjusted for age, sex, ethnicity, educational level, and use of stimulants, cocaine, 1-(1-phenylcyclohexyl)piperidine (PCP), psychedelics, and other drugs
(3,4-methylenedioxymethamphetamine [MDMA], alkyl nitrites, designer drugs).
bThe interaction term compares the effect size of cannabis use (separate for each level and, in the last 2 rows, as linear trend) in the siblings with the effect size
in controls.
cReference category.
dThe B linear trend is the summary change in schizotypy with 1 unit change in CIDI lifetime cannabis use.
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CROSS-SIBLING ASSOCIATIONS USING CAPE
There were 826 families who contributed a total of 1092
possible patient–unaffected sibling pairs; 826 families con-
tributed 1 sibling pair, 192 two pairs, 47 three pairs, 18
four pairs, 5 five pairs, and 4 six pairs. The cross-sibling
association of lifetime severity of CAPE positive symp-
toms was greater if the unaffected sibling had indicated
greater CIDI lifetime cannabis use (adjusted interaction
2=4.64, P=.03) (Table 4) and particularly if the un-
affected sibling scored positive for current cannabis use
by urinalysis (adjusted interaction 2=16.89, P .001)
(Figure4 and Table5). No significant interactions were
observed for the CAPE negative dimension, although find-
ings were directionally similar for cannabis use by uri-
nalysis (Figure 4 and Table 5).
MEDIATION VS MODERATION
Cross-sibling, cross-trait analyses of dichotomous life-
time cannabis use and psychosis were carried out in sib-
ling pairs. This revealed that CAPE positive dimension
scores in the patient did not predict cannabis use in the
sibling controlling for age, sex, ethnic group, and edu-
cational level of patient and sibling (21=1.27, P=.26), nor
did CAPE positive dimension scores in the sibling pre-
dict cannabis use in the patient (21=0.86, P=.35). Simi-
lar results were apparent for the CAPE negative dimen-
sion (21=0.19, P=.67, and 21=0.92, P=.34, respectively).
Analyses with cannabis assessed by urinalysis yielded simi-
lar inconclusive results (results not shown).
COMMENT
FINDINGS
Sensitivity to the psychotomimetic effects of cannabis was
examined in a case-control comparison involving 1057
unaffected siblings of patients with psychotic disorder
and 590 controls as well as a cross-sibling analysis of 1092
pairs of patients and their unaffected siblings. The re-
sults suggest that familial liability to psychosis is ex-
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Figure 2. Structured Interview for Schizotypy–Revised (SIS-R) negative
schizotypy score as a function of lifetime frequency of cannabis use in

























Figure 3. Positive and negative Structured Interview for Schizotypy–Revised
(SIS-R) schizotypy scores in controls and healthy siblings of patients
with psychotic disorder as a function of cannabis use assessed
by urinalysis.





















None 0.32 (0.35) 520 0c . . . 0.37 (0.40) 871 0c . . . 0c . . .
Positive 0.37 (0.42) 27 0.013 (−0.135 to 0.161) .86 0.56 (0.57) 73 0.197 (0.099 to 0.295) .001 4.19 .04
Negative Schizotypy
None 0.24 (0.23) 519 0c . . . 0.26 (0.25) 871 0c . . . 0c . . .
Positive 0.26 (0.22) 27 −0.008 (−0.102 to 0.086) .87 0.40 (0.34) 73 0.120 (0.057 to 0.182) .001 4.95 .03
Abbreviations: CI, confidence interval; SIS-R, Structured Interview for Schizotypy–Revised; ellipses, not applicable.
aAdjusted for age, sex, ethnicity, educational level, and use of amphetamines/3,4-methylenedioxymethamphetamine (MDMA) and cocaine by urinalysis.
bThe interaction term compares the effect size of cannabis use in siblings with the effect size of cannabis use in controls. The unadjusted interactions were as
follows: positive schizotypy, 2=2.71, P=.10; negative schizotypy, 2=4.77, P=.03.
cReference category.
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periences in response to cannabis. This result was evident
not only in the case-control comparison of individuals
at higher-than-average genetic risk using subclinical ex-
pression of psychosis as the outcome but also in the cross-
sibling comparison correlating levels of psychotic symp-
toms in patients and their unaffected siblings. Both patients
and siblings displayed higher rates of cannabis use, sug-
gesting that some of the apparent differential sensitivity
to the psychotomimetic effects of cannabis may in fact
represent a mechanism of psychotic disorder liability con-
tributing not only to sensitivity for cannabis but also to
the tendency to start using cannabis (gene-environment
correlation).50 However, the results of the cross-sibling,
cross-trait analyses examining whether cannabis use and
psychosis liability were associated with each other across
siblings did not support a gene-environment correlation.
This is in agreement with a previous study examining this
issue51 and with genetic epidemiology findings indicat-
ing that cannabis use in (early) adolescence—the rel-
evant timing of exposure with regard to psychotic dis-
order52—is influenced by environmental rather than
genetic factors.53 Thus, it is likely that the findings re-
flect, at least in part, moderation of the psychotomi-
metic effects of cannabis by familial liability to psy-
chotic disorder. The results in Table 3 indicate that current
cannabis use, defined as dichotomous presence by uri-
nalysis, was associated with an effect size of about 0.3
SD in the siblings, at least 15 times greater than the effect
size observed in the control group for both positive and
negative schizotypy. These differences suggest strong un-
derlying interaction between cannabis use and preexist-
ing psychosis liability. Similarly, cannabis use assessed
by urinalysis increased the sibling correlation by an ap-
proximate factor of 10 for positive symptoms and a fac-
tor of 2 (not statistically significant) for negative symp-
toms (Table 5).
It has been suggested that the main psychotropic
component of cannabis, 9-tetrahydrocannabinol,
interacts with dopaminergic neurotransmission.54 The
net result of this may be increased mesolimbic dopa-
mine signaling,55,56 which in turn may be associated
with psychotic symptoms.57 This theory remains at the
initial level of hypothesis testing58; the current findings
suggest that inclusion of genetic moderation may be
necessary to elucidate specific neurobiological mecha-
nisms. An initial observational study22 supported by
experimental work21 suggested an interaction between
cannabis use and the COMT Val158Met polymorphism.
Table 4. Cross-Sibling Associations in Lifetime Perceived Severity of Community Assessment of Psychic Experiences Symptoms
as a Function of Composite International Diagnostic Interview Lifetime Cannabis Use in the Unaffected Sibling

















None 0.20 (0.20) 598 0.68 (0.50) 574 0.010 (−0.023 to 0.045) .55 0c . . .
Less than weekly 0.18 (0.16) 131 0.69 (0.43) 122 0.035 (−0.046 to 0.115) .40 0.31 .58
Weekly 0.22 (0.22) 89 0.68 (0.49) 85 0.007 (−0.080 to 0.094) .88 0.01 .94
Daily 0.30 (0.25) 132 0.76 (0.52) 125 0.102 (0.035 to 0.169) .003 5.91 .02
Unadjusted B interaction linear trendd 2=4.26, P=.04
Adjusted B interaction linear trenda,d 2=4.64, P=.03
CAPE Negative Dimension
None 0.53 (0.38) 598 1.04 (0.56) 575 0.103 (0.045 to 0.162) .001 0c . . .
Less than weekly 0.51 (0.33) 131 1.02 (0.52) 122 0.037 (−0.096 to 0.169) .59 0.84 .36
Weekly 0.59 (0.43) 89 1.09 (0.49) 85 0.238 (0.071 to 0.404) .005 2.30 .13
Daily 0.73 (0.44) 132 1.09 (0.57) 125 0.064 (−0.055 to 0.182) .29 0.35 .55
Unadjusted B interaction linear trendd 2=0.00, P=.98
Adjusted B interaction linear trenda,d 2=0.00, P=.95
Abbreviations: CAPE, Community Assessment of Psychic Experiences; CI, confidence interval; CIDI, Composite International Diagnostic Interview; ellipses, not
applicable.
aAdjusted for age, sex, ethnicity, educational level, and use of stimulants, cocaine, 1-(1-phenylcyclohexyl)piperidine (PCP), psychedelics, and other drugs
(3,4-methylenedioxymethamphetamine [MDMA], alkyl nitrites, designer drugs).
bThe interaction tests whether the cross-sibling association at each level of cannabis use is increased compared with the reference category of no cannabis use.
cReference category.

























Figure 4. Patient–healthy sibling cross-sibling associations in Community
Assessment of Psychic Experiences (CAPE) positive and CAPE negative
symptoms as a function of cannabis use assessed by urinalysis in the
healthy sibling.
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A later study, however, could not replicate this find-
ing.59 Future work likely should focus on a more
extended range of genetic variation acting on pathways
associated with endocannabinoid-dopamine and other
biologically plausible interactions.
An important issue revealed by this study is that while
the relative effect sizes of differential sensitivity were high,
absolute effect sizes, for example, of cannabis on schizo-
typy in unaffected siblings, were small. It therefore fol-
lows that any study examining differential sensitivity will
require a very large sample to demonstrate differences
in sensitivity for an environmental risk factor between
groups.
The paradigm used in this study was based on the no-
tion that psychotic symptoms can be expressed below the
threshold of diagnosis and are meaningful in relation to
the clinical phenotype. Meta-analytic work of subdiag-
nostic expression of psychotic experiences in the gen-
eral population has shown etiological, psychopathologi-
cal, and longitudinal continuity between the extended
subclinical phenotype and clinical expression of psy-
chotic disorder as well as a similar age-related develop-
mental pattern of expression60; a recent landmark gen-
eral population birth cohort study confirmed this pattern
of findings.14 The current findings also support this no-
tion as expression of psychosis, measured by the CAPE,
was correlated in patient-sibling pairs, although this was
contingent on concurrent cannabis use (Table 5).
The results were more apparent and effect sizes were
stronger with recent cannabis use as assessed by urinaly-
sis. This suggests that differential sensitivity predomi-
nantly reflected response of schizotypal signs and symp-
toms to recent cannabis use in genetically vulnerable
siblings rather than longer-term stable expression of
schizotypy associated with developmental lifetime ex-
posure to cannabis.
STRENGTHS AND LIMITATIONS
Strengths of the study include the within-study sibling-
control and cross-sibling replication of differential sen-
sitivity, the large sample, and the exposure assessment
by urinalysis. In addition, the patient-sibling correla-
tional analysis has the important advantage of auto-
matic control for a range of confounders that may affect
case-control comparisons in unrelated subjects given that
siblings share a range of demographic factors and life cir-
cumstances that may affect mental health and substance
use.
The results should be interpreted in light of the fol-
lowing limitations. As schizotypy is not a measure that
can be assessed in patients with psychotic disorder (ceil-
Table 5. Cross-Sibling Associations in Community Assessment of Psychic Experiences Dimensions as a Function of Current Cannabis


















None 0.20 (0.19) 806 0.68 (0.49) 772 0.025 (−0.007 to 0.057) .12 0c . . .
Positive 0.32 (0.30) 65 0.83 (0.47) 57 0.278 (0.162 to 0.396) .001 16.89 .001
CAPE Negative Symptoms
None 0.55 (0.39) 806 1.05 (0.55) 773 0.103 (0.047 to 0.160) .001 0c . . .
Positive 0.77 (0.44) 65 1.10 (0.54) 56 0.256 (0.042 to 0.470) .02 1.87 .17
Abbreviations: CAPE, Community Assessment of Psychic Experiences; CI, confidence interval; ellipses, not applicable.
aAdjusted for age, sex, ethnicity, educational level, and use of amphetamines/3,4-methylenedioxymethamphetamine (MDMA) and cocaine by urinalysis.
bThe interaction tests whether the cross-sibling association is significantly greater in the cannabis-positive group compared with the cannabis-negative group.
The unadjusted interactions were as follows: positive schizotypy, 2=17.99, P  .001; negative schizotypy, 2=1.38, P=.24.
cReference category.
Genetic Risk and Outcome in Psychosis (GROUP) Investigators
Authors
Rene´ S. Kahn, MD, PhD, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center
Utrecht, Utrecht, the Netherlands; Don H. Linszen, MD, PhD, Department of Psychiatry, Academic Medical Centre, Uni-
versity of Amsterdam, Amsterdam, the Netherlands; Jim van Os, MD, PhD, South Limburg Mental Health Research and Teach-
ing Network, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands, and King’s College London, King’s
Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, United Kingdom; Durk Wiersma, PhD,
Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Richard
Bruggeman, MD, PhD, Department of Psychiatry, University Medical Center Groningen, University of Groningen; Wiepke
Cahn, MD, PhD, Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht;
Lieuwe de Haan, MD, PhD, Department of Psychiatry, Academic Medical Centre, University of Amsterdam; Lydia
Krabbendam, PhD, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht University Medical
Centre; and Inez Myin-Germeys, PhD, South Limburg Mental Health Research and Teaching Network, EURON, Maastricht
University Medical Centre.
(REPRINTED) ARCH GEN PSYCHIATRY/ VOL 68 (NO. 2), FEB 2011 WWW.ARCHGENPSYCHIATRY.COM
145
©2011 American Medical Association. All rights reserved.
 at Rijksuniversiteit Groningen, on June 20, 2011 www.archgenpsychiatry.comDownloaded from 
ing effects) and, vice versa, an interview for clinical psy-
chotic disorder is not applicable to healthy siblings (floor
effects), the psychosis measure used in the cross-sibling
analysis was self-reported psychotic experiences using the
CAPE. It could be argued that the CAPE does not mea-
sure the same phenotype in patients and siblings. How-
ever, for the purpose of the cross-sibling association analy-
ses, phenotypic similarity is not required; what is required
is that the measure in both groups taps into the same un-
derlying liability, at the level of behavioral expression of
liability in the siblings and at the level of illness-related
symptoms in the patients. As previous work has shown
strong concurrent validity of the CAPE with schizotypy
in healthy controls11 and concurrent validity with posi-
tive psychotic symptoms in patients, regardless of level
of insight,61 the cross-sibling association can be inter-
preted as the sibling correlation in the level of psychosis
liability.
The fact that our mediation analyses were inconclu-
sive suggests that the difference in use between patients/
siblings and controls is not due to shared liability for psy-
chotic disorder (therefore not affecting the interpretation
of the moderation analyses) but to another factor. One
explanation is that patients and siblings as a population
are more closely matched to each other than the con-
trols so that sampling variation will affect both groups
in the same direction compared with controls. Al-
though efforts were made to ensure that controls were
sampled from the same population as the cases/siblings,
differences may always exist. As our study focused on dif-
ferential sensitivity to cannabis and not on differences
in the rate of cannabis use per se, this is not important
for the results, at least to the degree that group differ-
ences in the rate of cannabis use are not the result of me-
diation. Previous work in epidemiological samples has
reported no differences in the rate of cannabis use be-
tween controls and siblings of patients with psychotic
disorder.51
In conclusion, differential sensitivity to cannabis was
demonstrated in the form of greater response to recent
cannabis use in individuals at higher-than-average risk
for psychotic disorder and related disorders. These find-
ings provide a rationale for a more detailed analysis of
the molecular substrate underlying differential canna-
bis sensitivity.
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